Book contents
- Frontmatter
- Contents
- Contributors
- Introduction
- I Critical Concepts
- II Therapeutic Areas
- 10 Oncologic Drugs
- 11 Pharmacogenetics and Pharmacogenomics of Cardiovascular Disease
- 12 Statin-Induced Muscle Toxicity
- 13 Genomics of the Drug-Induced Long-QT Syndrome
- 14 Pharmacogenetics of Diabetes
- 15 Pharmacogenetics – Therapeutic Area – Respiratory
- 16 Pharmacogenomics Associated with Therapy for Acid-Related Disorders
- 17 Pharmacogenetics of Rheumatology: Focus on Rheumatoid Arthritis
- 18 Pharmacogenetics of Obstetric Therapeutics
- 19 Pharmacogenomics of Psychiatric Drugs
- 20 Pain and Anesthesia
- 21 HIV and Antiretroviral Therapy
- 22 Application of Pharmacogenetics and Pharmacogenomics in Pediatrics: What Makes Children Different?
- References
18 - Pharmacogenetics of Obstetric Therapeutics
from II - Therapeutic Areas
Published online by Cambridge University Press: 05 June 2012
Book contents
- Frontmatter
- Contents
- Contributors
- Introduction
- I Critical Concepts
- II Therapeutic Areas
- 10 Oncologic Drugs
- 11 Pharmacogenetics and Pharmacogenomics of Cardiovascular Disease
- 12 Statin-Induced Muscle Toxicity
- 13 Genomics of the Drug-Induced Long-QT Syndrome
- 14 Pharmacogenetics of Diabetes
- 15 Pharmacogenetics – Therapeutic Area – Respiratory
- 16 Pharmacogenomics Associated with Therapy for Acid-Related Disorders
- 17 Pharmacogenetics of Rheumatology: Focus on Rheumatoid Arthritis
- 18 Pharmacogenetics of Obstetric Therapeutics
- 19 Pharmacogenomics of Psychiatric Drugs
- 20 Pain and Anesthesia
- 21 HIV and Antiretroviral Therapy
- 22 Application of Pharmacogenetics and Pharmacogenomics in Pediatrics: What Makes Children Different?
- References
Summary
Obstetric pharmacology, in many respects, is still in its infancy. Because of valid concerns about the safety of drugs to both the mother and developing fetus, not as much data exist for drugs in pregnancy. There is also a distinct paucity of data regarding pharmacogenetics in pregnancy. At this time, many of the potential pharmacogenetic applications to pregnancy drug therapy are theoretical. This chapter summarizes the drug therapy for five of the major pregnancy conditions/complications, along with a brief discussion of potential pharmacogenetic or individualized pharmacotherapy applications for each. These conditions are preterm labor, depression, diabetes, the nausea and vomiting of pregnancy (NVP), and hypertension.
Preterm Labor
Preterm birth is the leading cause of morbidity and mortality in newborns in the United States. More than 12.5 percent of all live births are preterm, accounting for a large amount of health care spending for infants. The number of preterm births in the United States, as well as in many other industrialized countries, continues to rise. Preterm labor is the most common cause of hospitalization of pregnant women (1). Although the incidence and burden of preterm birth are relatively clear, the causes of preterm labor are not well understood (2).
- Type
- Chapter
- Information
- Principles of Pharmacogenetics and Pharmacogenomics , pp. 202 - 216Publisher: Cambridge University PressPrint publication year: 2012
References
Epidemiologic characteristics of preterm delivery: etiologic heterogeneityAm J Obstet Gynecol 1991 164 467Google Scholar
2000
Chapter 36: Preterm birthWilliams ObstetricsNew YorkMcGraw-Hill 2010
2006 1966
2004
2003
2002
2005
Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey ReplicationArch Gen Psychiatry 2005 62 593Google Scholar
Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity SurveyArch Gen Psychiatry 1994 51 8Google Scholar
A prospective study of emotional disorders in childbearing womenBr J Psychiatry 1984 144 35Google Scholar
A systematic review of the literature exploring the role of primary care in genetic servicesFam Pract 1999 16 426Google Scholar
A standardized interview that differentiates pregnancy and postpartum symptoms from perinatal clinical depressionBirth 1990 17 121Google Scholar
What will it take to reap the clinical benefits of pharmacogenomics?Food Drug Law J 2006 61 753Google Scholar
Dose of selective serotonin uptake inhibitors across pregnancy: clinical implicationsDepress Anxiety 2000 11 51Google Scholar
Diagnostic and Statistical Manual of Mental DisordersWashington, DCAmerican Psychiatric Association 1994
A randomized double-dummy comparison between indomethacin and nylidrin in threatened preterm laborObstet Gynecol 1991 78 1093Google Scholar
Depression as a potential causal factor in subsequent miscarriage in recurrent spontaneous abortersHum Reprod 2002 17 2580Google Scholar
Maternal corticotropin-releasing hormone is increased with impending preterm birthJ Clin Endocrinol Metab 1998 83 1585Google Scholar
Maternal prenatal depressive symptoms and spontaneous preterm births among African-American women in Baltimore, MarylandAm J Epidemiol 2002 156 797Google Scholar
Maternal depressive symptoms and the risk of poor pregnancy outcome. Review of the literature and preliminary findingsEpidemiol Rev 1995 17 165Google Scholar
Why current breast pathology practices must be evaluated. A Susan G. Komen for the Cure white paper: June 2006Breast J 2007 13 443Google Scholar
A comparison of magnesium sulfate and alcohol for the prevention of premature laborAm J Obstet Gynecol 1977 129 1Google Scholar
Anxiety and depression in mothers of low birthweight and very low birthweight infants: birth through 5 monthsIssues Compr Pediatr Nurs 1990 13 97Google Scholar
The relationship between psychological distress during pregnancy and birth weight for gestational ageActa Obstet Gynecol Scand 1996 75 32Google Scholar
Depressive symptomatology during pregnancy: evidence for an association with decreased fetal growth in pregnancies of lower social class womenHealth Psychol 2000 19 535Google Scholar
The impact of prenatal maternal stress and optimistic disposition on birth outcomes in medically high-risk womenHealth Psychol 2000 19 544Google Scholar
The Randomized Nitric Oxide Tocolysis Trial (RNOTT) for the treatment of preterm laborAm J Obstet Gynecol 2004 191 683Google Scholar
Psychosocial distress during pregnancy and the risk of infantile colic: a follow-up studyActa Paediatr 2003 92 811Google Scholar
Further study of the inhibition of premature labor by indomethacin. Part II double-blind studyJ Perinat Med 1984 12 25Google Scholar
87, November 2007. Use of psychiatric medications during pregnancy and lactationObstet Gynecol 2007 110 1179Google Scholar
Depression and the parenting of young children: making the case for early preventive mental health servicesHarv Rev Psychiatry 2000 8 148Google Scholar
Psychopathology in the children (ages 6–18) of depressed and normal parentsJ Am Acad Child Psychiatry 1984 23 78Google Scholar
A double-blind randomized study of fetal side effects during and after the short-term maternal administration of indomethacin, sulindac, and nimesulide for the treatment of preterm laborAm J Obstet Gynecol 2003 188 1046Google Scholar
Ethically justified clinically comprehensive guidelines for the management of the depressed pregnant patientAm J Obstet Gynecol 1996 174 1Google Scholar
Controlled clinical trial of interpersonal psychotherapy versus parenting education program for depressed pregnant womenAm J Psychiatry 2003 160 555Google Scholar
Prescribing antidepressants to pregnant women: what is a family physician to doCan Fam Physician 2007 53 1412Google Scholar
Antidepressant drugs during pregnancy and infant congenital heart defectReprod Toxicol 2006 21 221Google Scholar
Newer antidepressants in pregnancy and rates of major malformations: a meta-analysis of prospective comparative studiesPharmacoepidemiol Drug Saf 2005 14 823Google Scholar
Risks associated with selective serotonin reuptake inhibitors in pregnancyObstet Gynecol 2005 106 1289Google Scholar
Selective serotonin reuptake inhibitors and adverse pregnancy outcomesAm J Obstet Gynecol 2006 194 961Google Scholar
Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defectsN Engl J Med 2007 356 2684Google Scholar
First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defectsN Engl J Med 2007 356 2675Google Scholar
Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroidsHum Mol Genet 2004 13 1353Google Scholar
The outcome of pregnancy in 689 women exposed to therapeutic doses of antidepressants. A collaborative study of the European Network of Teratology Information Services (ENTIS)Reprod Toxicol 1996 10 285Google Scholar
A multicentre prospective controlled study to determine the safety of trazodone and nefazodone use during pregnancyCan J Psychiatry 2003 48 106Google Scholar
Neonate characteristics after maternal use of antidepressants in late pregnancyArch Pediatr Adolesc Med 2004 158 312Google Scholar
Mirtazapine (Remergil) for treatment resistant hyperemesis gravidarum: rescue of a twin pregnancyArch Gynecol Obstet 2003 268 219Google Scholar
Newer antidepressants in pregnancy: prospective outcome of a case seriesReprod Toxicol 2004 19 235Google Scholar
Psychotropic drugs in pregnancy: a case-control studyProg Neuropsychopharmacol Biol Psychiatry 2005 29 333Google Scholar
Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective comparative studyAm J Obstet Gynecol 2005 192 932Google Scholar
Perinatal outcome following third trimester exposure to paroxetineArch Pediatr Adolesc Med 2002 156 1129Google Scholar
Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applicationsJAMA 2005 293 2372Google Scholar
Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehaviorPediatrics 2004 113 368Google Scholar
Taking antidepressants during late pregnancy. How should we advise women?Can Fam Physician 2005 51 1077Google Scholar
Birth outcomes after prenatal exposure to antidepressant medicationAm J Obstet Gynecol 2003 188 812Google Scholar
Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposureJ Clin Psychiatry 2004 65 230Google Scholar
Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancyJ Pediatr 2003 142 402Google Scholar
Neurodevelopment of children exposed in utero to antidepressant drugsN Engl J Med 1997 336 258Google Scholar
Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled studyAm J Psychiatry 2002 159 1889Google Scholar
Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatmentJAMA 2006 295 499Google Scholar
2000 880
Clinical management guidelines for obstetrician-gynecologists (replaces Technical Bulletin No. 200, December 1994Obstet Gynecol 2001 98 525Google Scholar
Type 2 diabetes in pregnancy: a wolf in sheep's clothingAust N Z J Obstet Gynaecol 2005 45 479Google Scholar
Chapter 52: DiabetesWilliams ObstetricsNew YorkMcGraw-Hill 2010
A comparison of glyburide and insulin in women with gestational diabetes mellitusN Engl J Med 2000 343 1134Google Scholar
Prevalence and severity of nausea and vomiting of pregnancy and effect of vitamin supplementationClin Invest Med 1999 22 106Google Scholar
Psychosocial morbidity among women with nausea and vomiting of pregnancy: prevalence and association with anti-emetic therapyJ Psychosom Obstet Gynaecol 2000 21 129Google Scholar
Nausea and vomiting of pregnancy: the problem of perception–is it really a disease?Am J Obstet Gynecol 2002 186 S182Google Scholar
The burden of illness of severe nausea and vomiting of pregnancy in the United StatesAm J Obstet Gynecol 2002 186 S220Google Scholar
Therapeutic abortions due to severe morning sickness. Unacceptable combinationCan Fam Physician 1997 43 1055Google Scholar
Development of a health-related quality of life instrument for nausea and vomiting of pregnancyAm J Obstet Gynecol 2002 186 S232Google Scholar
Nausea and vomiting of pregnancy: an obstetric syndromeAm J Obstet Gynecol 2002 186 S184Google Scholar
Vitamin B6 is effective therapy for nausea and vomiting of pregnancy: a randomized, double-blind placebo-controlled studyObstet Gynecol 1991 78 33Google Scholar
Pyridoxine for nausea and vomiting of pregnancy: a randomized, double-blind, placebo-controlled trialAm J Obstet Gynecol 1995 173 881Google Scholar
Bendectin in the treatment of nausea and vomiting in pregnancyObstet Gynecol 1959 14 688Google Scholar
Treatment of nausea and vomiting in pregnancy: an updated algorithmCan Fam Physician 2007 53 2109Google Scholar
Measuring drug effectiveness by default: the case of BendectinCan J Public Health 1995 86 66Google Scholar
Bendectin and birth defects: I. A meta-analysis of the epidemiologic studiesTeratology 1994 50 27Google Scholar
Pregnancy outcome following first trimester exposure to antihistamines: meta-analysisAm J Perinatol 1997 14 119Google Scholar
Nausea and vomiting in pregnancy: a comparative European studyEur J Obstet Gynecol Reprod Biol 1998 76 1Google Scholar
Metoclopramide: a review of its pharmacological properties and clinical useDrugs 1976 12 81Google Scholar
Hyperemesis gravidarum and nonspecific abnormal EEG findings: a preliminary reportJ Reprod Med 2006 51 623Google Scholar
Home subcutaneous metoclopramide therapy for hyperemesis gravidarumJ Perinatol 2000 20 359Google Scholar
Comparison of three outpatient regimens in the management of nausea and vomiting in pregnancyJ Perinatol 2003 23 531Google Scholar
The safety of ondansetron for nausea and vomiting of pregnancy: a prospective comparative studyBJOG 2004 111 940Google Scholar
A pilot study of intravenous ondansetron for hyperemesis gravidarumAm J Obstet Gynecol 1996 174 1565Google Scholar
Effectiveness and safety of ginger in the treatment of pregnancy-induced nausea and vomitingObstet Gynecol 2005 105 849Google Scholar
Use of herbal drugs in pregnancy: a survey among 400 Norwegian womenPharmacoepidemiol Drug Saf 2004 13 371Google Scholar
Prospective comparative study of the safety and effectiveness of ginger for the treatment of nausea and vomiting in pregnancyAm J Obstet Gynecol 2003 189 1374Google Scholar
Ginger for nausea and vomiting in pregnancy: randomized, double-masked, placebo-controlled trialObstet Gynecol 2001 97 577Google Scholar
The efficacy of methylprednisolone in the treatment of hyperemesis gravidarum: a randomized, double-blind, controlled studyAm J Obstet Gynecol 1998 179 921Google Scholar
A randomized, placebo-controlled trial of corticosteroids for hyperemesis due to pregnancyObstet Gynecol 2003 102 1250Google Scholar
Maternal corticosteroid use and risk of selected congenital anomaliesAm J Med Genet 1999 86 242Google Scholar
Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studiesTeratology 2000 62 385Google Scholar
Corticosteroids during pregnancy and oral clefts: a case-control studyTeratology 1998 58 2Google Scholar
Catalog of Teratogenic AgentsBaltimore, MDJohns Hopkins University Press 2001
Chronic hypertension in pregnancy. ACOG Committee on Practice BulletinsObstet Gynecol 2001 98 177Google Scholar
Diagnosis and management of gestational hypertension and preeclampsiaObstet Gynecol 2003 102 181Google Scholar
Treatment of hypertension in pregnancy: effect of atenolol on maternal disease, preterm delivery, and fetal growthObstet Gynecol 2001 98 427Google Scholar
Risks and benefits of beta-receptor blockers for pregnancy hypertension: overview of the randomized trialsEur J Obstet Gynecol Reprod Biol 2000 88 15Google Scholar
Overview of randomised trials of diuretics in pregnancyBr Med J (Clin Res Ed) 1985 290 17Google Scholar
2000
Chapter 45: Chronic hypertensionWilliams ObstetricsNew YorkMcGraw-Hill 2010 983